Yichang Three Gorges Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Renfu Pharmaceutical Group. It is a comprehensive biopharmaceutical enterprise that researches and produces antibiotic raw materials, amino acid series high-capacity injections, and animal drug preparations. It is a national high-tech enterprise. In recent years, the company has successively won titles such as "Excellent Enterprise for Exporting Raw Materials of Pharmaceutical Industry in Hubei Province", "Top 10 Export Enterprises in Hubei Province for Foreign Exchange Earnings", and "Hidden Champion Technology Little Giant in Subdivision Fields of Hubei Province's Pillar Industries". The registered trademark of "Three Gorges Brand" has been recognized as a well-known trademark in Yichang City.

The company currently covers an area of 300000 square meters and has four industrial bases, including Yichang High tech Zone Industrial Park, Dianjun Industrial Park, Xiaoting Branch, and the newly built Yuan'an Branch. It is a large global supplier of raw materials for neomycin sulfate, with a segmented product line covering veterinary neomycin sulfate, flavomycin sulfate, and prescription human neomycin sulfate. The product has been certified by the US FDA and the EU CEP, and neomycin sulfate has been awarded the title of "Manufacturing Champion Product" by the Chinese Ministry of Industry and Information Technology, with a global market share of over 70%. The company is also one of the earliest manufacturers of amino acid high-capacity injections in China. The "Three Gorges Brand" series of amino acid high-capacity injections has been recognized as a "famous brand product" and "high-quality product" in Hubei Province.

The company currently has about 700 employees, with 30% of them being professional and technical personnel. It has established a well-equipped professional research and development team and established industry academia research platforms with multiple universities. It has done a lot of research and development work in improving production technology and new products. Currently, it has 30 authorized patents and 30 scientific and technological achievements. During the 14th Five Year Plan period, the company focused on producing strong neomycin raw materials and veterinary preparations, researching and developing veterinary pet drugs and vaccines. Leveraging the advantages of Renfu Pharmaceutical Group in human anesthetics, the company developed veterinary anesthesia products, concentrated resources on the field of veterinary drugs, further increased the production and sales of veterinary drug series products, and made greater contributions to local development.